2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1913

Inter-Omic Analysis Reveals Functional Relationship between Diverse Gut Microbiota and Dysregulated Host Immune Response in HLA-B27-Mediated Experimental Spondyloarthritis
Abstract Number: 1463

Interaction between Methotrexate and BAFF for Preventing Immunization Against TNF-α Inhibitors By Increasing Adenosine and Regulatory B-Cell Subsets
Abstract Number: 1655

Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus
Abstract Number: 1728

Interferon Gamma (IFN-γ) Subpopulations in Skin Homing T Cells of Localized Scleroderma
Abstract Number: 1369

Interferon Gamma Signature Genes and CXCL10 As New Biomarkers in Early Stage of Rheumatoid Arthritis
Abstract Number: 2927

Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Abstract Number: 1658

Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways
Abstract Number: 754

Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells
Abstract Number: 2349

Interferon Signature in Childhood Rheumatic Diseases
Abstract Number: 831

Interferon-Alpha Disrupts Tolerance in a Mouse Model of B Cell Anergy
Abstract Number: 866

Interferon-Alpha Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis
Abstract Number: 2813

Interferon-Induced APOL1 over-Expression Causes Autophagic Dysfunction and Mitochondrial Stress in Risk Variant-Carrying Endothelial Cells
Abstract Number: 2814

Interferon-β Production By B Cells Promotes B Cell Survival and Is Strongly Associated with Active Disease in African Americans with SLE
Abstract Number: 1930

Interleukin 1β Decreases Capacity for Repair Human Cartilage Lesions By Mesenchymal Stromal Cells on Collagen/Proteoglycan Scaffolds
Abstract Number: 367

Interleukin-1 Receptor Antagonist Is a Potential Treatment for Undifferentiated Autoinflammatory Syndromes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].